BerGenBio Valuation
Is BGBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BGBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BGBIO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BGBIO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BGBIO?
Other financial metrics that can be useful for relative valuation.
What is BGBIO's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NOK 400.25m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 384.1x |
Enterprise Value/EBITDA | -1.2x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does BGBIO's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3x | ||
LYTIX Lytix Biopharma | 5.8x | n/a | NOK 341.3m |
TRMED Thor Medical | 1.1x | n/a | NOK 274.3m |
NANOV Nordic Nanovector | 3.6x | n/a | NOK 231.8m |
ABS Arctic Bioscience | 1.5x | -7.6% | NOK 360.2m |
BGBIO BerGenBio | 2.3x | -25.0% | NOK 400.3m |
Price-To-Book vs Peers: BGBIO is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (2.8x).
Price to Earnings Ratio vs Industry
How does BGBIO's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Book vs Industry: BGBIO is good value based on its Price-To-Book Ratio (2.3x) compared to the European Biotechs industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is BGBIO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 2.3x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate BGBIO's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | NOK 10.24 | NOK 20.00 +95.3% | 68.2% | NOK 38.00 | NOK 5.00 | n/a | 3 |
Sep ’25 | NOK 10.90 | NOK 20.00 +83.5% | 68.2% | NOK 38.00 | NOK 5.00 | n/a | 3 |
Aug ’25 | NOK 13.23 | NOK 30.67 +131.8% | 92.1% | NOK 70.00 | NOK 5.00 | n/a | 3 |
Jul ’25 | NOK 11.80 | NOK 33.33 +182.4% | 81.5% | NOK 70.00 | NOK 5.00 | n/a | 3 |
Jun ’25 | NOK 14.17 | NOK 33.33 +135.2% | 81.5% | NOK 70.00 | NOK 5.00 | n/a | 3 |
May ’25 | NOK 14.50 | NOK 76.67 +428.7% | 114.2% | NOK 200.00 | NOK 5.00 | n/a | 3 |
Apr ’25 | NOK 19.40 | NOK 76.67 +295.2% | 114.2% | NOK 200.00 | NOK 5.00 | n/a | 3 |
Mar ’25 | NOK 19.52 | NOK 76.67 +292.8% | 114.2% | NOK 200.00 | NOK 5.00 | n/a | 3 |
Feb ’25 | NOK 26.75 | NOK 76.67 +186.6% | 114.2% | NOK 200.00 | NOK 5.00 | n/a | 3 |
Jan ’25 | NOK 27.80 | NOK 76.67 +175.8% | 114.2% | NOK 200.00 | NOK 5.00 | n/a | 3 |
Dec ’24 | NOK 17.90 | NOK 76.67 +328.3% | 114.2% | NOK 200.00 | NOK 5.00 | n/a | 3 |
Nov ’24 | NOK 19.74 | NOK 568.33 +2,779.1% | 116.8% | NOK 1,500.00 | NOK 5.00 | n/a | 3 |
Oct ’24 | NOK 10.78 | NOK 568.33 +5,172.1% | 116.8% | NOK 1,500.00 | NOK 5.00 | n/a | 3 |
Sep ’24 | NOK 11.10 | NOK 568.33 +5,020.1% | 116.8% | NOK 1,500.00 | NOK 5.00 | NOK 10.90 | 3 |
Aug ’24 | NOK 10.04 | NOK 1,501.67 +14,856.8% | 81.4% | NOK 3,000.00 | NOK 5.00 | NOK 13.23 | 3 |
Jul ’24 | NOK 8.60 | NOK 1,533.33 +17,729.5% | 77.2% | NOK 3,000.00 | NOK 100.00 | NOK 11.80 | 3 |
Jun ’24 | NOK 36.25 | NOK 1,533.33 +4,129.9% | 77.2% | NOK 3,000.00 | NOK 100.00 | NOK 14.17 | 3 |
May ’24 | NOK 183.00 | NOK 1,533.33 +737.9% | 77.2% | NOK 3,000.00 | NOK 100.00 | NOK 14.50 | 3 |
Apr ’24 | NOK 481.40 | NOK 1,800.00 +273.9% | 49.1% | NOK 3,000.00 | NOK 900.00 | NOK 19.40 | 3 |
Mar ’24 | NOK 655.00 | NOK 1,800.00 +174.8% | 49.1% | NOK 3,000.00 | NOK 900.00 | NOK 19.52 | 3 |
Feb ’24 | NOK 695.00 | NOK 1,800.00 +159.0% | 49.1% | NOK 3,000.00 | NOK 900.00 | NOK 26.75 | 3 |
Jan ’24 | NOK 747.00 | NOK 1,800.00 +141.0% | 49.1% | NOK 3,000.00 | NOK 900.00 | NOK 27.80 | 3 |
Dec ’23 | NOK 867.00 | NOK 1,800.00 +107.6% | 49.1% | NOK 3,000.00 | NOK 900.00 | NOK 17.90 | 3 |
Nov ’23 | NOK 742.00 | NOK 1,200.00 +61.7% | 25.0% | NOK 1,500.00 | NOK 900.00 | NOK 19.74 | 2 |
Oct ’23 | NOK 617.00 | NOK 1,200.00 +94.5% | 25.0% | NOK 1,500.00 | NOK 900.00 | NOK 10.78 | 2 |
Sep ’23 | NOK 1,103.00 | NOK 3,850.00 +249.0% | 42.9% | NOK 5,500.00 | NOK 2,200.00 | NOK 11.10 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.